ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Comparison of plasma p-tau217/Aβ42, p-tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of plasma p-tau217 against amyloid PET: A meta-analysis of technical platform variability and ratio versus single marker comparisons.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women.JAMA network open · 2026Trial
- Multimorbidity and Associations with Cognition and Alzheimer's Disease Biomarkers.Annals of neurology · 2026Article
- Optimized plasma p-tau217 and p-tau217/Aβ42 cutoffs enhance detection of pre-clinical Alzheimer's disease across diverse participants.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- The countdown paradox: time-varying analysis of biomarker-clock age and symptom onset.medRxiv : the preprint server for health sciences · 2026Article
- Multicenter validation of plasma p-tau217/ amyloid beta 1-42 ratio in symptomatic Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Reliable quantification of renal function from frozen blood samples.medRxiv : the preprint server for health sciences · 2026Article
- Vulnerability of anterior medial temporal lobe subregions to early tau-related neurodegeneration in Alzheimer's disease: Converging evidence from tau-PET and plasma p-tau217.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Tau and β-Amyloid Relevant Pathology as a Central Therapeutic Target in Alzheimer's Disease.Biomolecules · 2026Review
- Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.Brain : a journal of neurology · 2026Article
- Electronic Health Records to Test Multimorbidity Influences to Plasma Biomarker Interpretation for Alzheimer's Disease.Annals of neurology · 2026Article
- Midlife sleep characteristics and Alzheimer's disease biomarkers 20 years later.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Ancestry-specific effects ofmedRxiv : the preprint server for health sciences · 2026Article
- Association of plasma p-tau and p-tau/Aβ ratio with Alzheimer's pathology.The journal of prevention of Alzheimer's disease · 2026Article
- The evolving landscape of amyloid-targeting therapies in Alzheimer's disease: progress and challenges.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Sex differences in Alzheimer's disease plasma biomarker levels and clinical utility.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma p-tau217 and incident mild cognitive impairment and dementia in older women: 25-year prospective study in The Women's Health Initiative Memory Study.medRxiv : the preprint server for health sciences · 2025Article
- Comparison of plasma p-tau217/Aβ42, p-tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
Abstract
introductionIn clinically and racially diverse training and test sets, we evaluated and validated Alzheimer's disease (AD) plasma biomarkers: phosphorylated tau-217 (p-tau217), amyloid beta 1-42/1-40 (Aβ42/Aβ40), and p-tau217/Aβ42.
methodsInclusion criteria were available plasma, race (people who self-identified as Black/African American [pBlack] or White [pWhite]), cognitive status (normal, mild cognitive impairment [MCI], dementia), and
resultsIn the test set, plasma p-tau217/Aβ42 had the highest accuracy (pBlack: 0.88, pWhite: 0.91) and lowest proportion of intermediate classifications (≤0.16), with no classification difference by race (odds ratio [OR] = 1.45, 95% confidence interval [CI] = 0.66-2.95, p = 0.33). False negatives were more likely to be cognitively normal (vs mild cognitive impairment [MCI]; OR = 7.79, 95% CI = 2.33-40.81, p = 5.1e-05) than correct classifications. DISCUSSION: Plasma p-tau217/Aβ42 had high accuracy to detect AD, with comparable performance across race. HIGHLIGHTS: We tested plasma phosphorylated tau-217 (p-tau217)/amyloid beta (Aβ)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.